Search
SOLACI Congress
HomeFileCoronary disease

Coronary disease

View Category

Acute coronary syndromes

Microvascular Resistant Reserve: Impact on STEMI Patients

Coronary Microvascular Dysfunction (CMD) is being increasingly considered a common consequence of STEMI. Its presence partly explains...
solaci -
Learn More
Chronic Ischemic cardiopathy

REPLICA-EPICA 18 Registry: Using IVL in Calcified Coronary Lesions

The presence of calcification in the coronary arteries (CAC) remains the main challenge in the percutaneous treatment...
solaci -
Learn More
Chronic Coronary Syndromes

Is Intravascular Lithotripsy Equally Effective in All Coronary Calcification Patterns?

Coronary calcifications pose a complex challenge with a high incidence (25% of all angioplasties), thus implying difficult...
solaci -
Learn More
Acute coronary syndromes

Functional Assessment Using QFR for the Revascularization of Non-Culprit Lesions in AMI Patients

Nowadays, evidence from studies and meta-analyses has demonstrated the benefits of complete revascularization compared to culprit-vessel-only revascularization...
solaci -
Learn More
Coronary disease

EuroPCR 2024 | 2 Year Outcomes of the New Sirolimus Eluting Bioadaptor vs Resolute Onyx Zotarolimus Elulting Stent

Stent related adverse events after the first year see a constant 2-3% annual increase, reaching 20% by...
solaci -
Learn More
Acute coronary syndromes

EuroPCR 2024 | Complete revascularization affects clinical outcomes? REVIVED.BCIS2 Insights

Complete revascularization has shown in several studies and meta-analysis a benefit in mortality vs. incomplete revascularization. The REVIVED-BCIS...
solaci -
Learn More
Chronic Ischemic cardiopathy

EuroPCR 2024 | CALIPSO: CTO vs Angiography Guided Treatment of Calcified Lesions

The presence of calcified lesions worsens percutaneous coronary intervention prognosis, presenting more restenosis, thrombosis and need for...
solaci -
Learn More
Acute coronary syndromes

EuroPCR 2024 | DOCTORS-LM Trial: CTO Optimizes Stent Outcomes in Left Main Disease?

The aim of this randomized open study was to determine whether CTO guided left main percutaneous coronary...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Dr. Omar Tupayachi - 0
Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Dr. Omar Tupayachi - 0
Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Dr. Juan Manuel Pérez - 0
Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy